BridgeBio Pharma BBIO Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's accounts payable?
- BridgeBio Pharma (BBIO) reported accounts payable of $29.06M in Q1 2026.
- How has BridgeBio Pharma's accounts payable changed year-over-year?
- BridgeBio Pharma's accounts payable increased by 5.6% year-over-year, from $27.53M to $29.06M.
- What is the long-term trend for BridgeBio Pharma's accounts payable?
- Over 4 years (2021 to 2025), BridgeBio Pharma's accounts payable has grown at a 17.7% compound annual growth rate (CAGR), from $56.59M to $108.59M.
- What does accounts payable mean?
- Money the company owes to its suppliers for goods or services already received.
- How do you interpret accounts payable?
- An increase can signal improved cash management or delayed payments, while a decrease may indicate faster settlement of obligations.
- How does accounts payable compare across companies?
- Accounts payable levels are typically correlated with the intensity of clinical trial activity and external research outsourcing.